Deflazacort
| Clinical data | |
|---|---|
| Trade names | Emflaza, Calcort, others | 
| AHFS/Drugs.com | Monograph | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 40% | 
| Metabolism | By plasma esterases, to active metabolite | 
| Elimination half-life | 1.1–1.9 hours (metabolite) | 
| Excretion | Kidney (70%) and fecal (30%) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.034.969 | 
| Chemical and physical data | |
| Formula | C25H31NO6 | 
| Molar mass | 441.524 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Deflazacort, sold under the brand name Calcort among others, is a glucocorticoid belonging to acetonides or O-isopropylidene derivative. It is used as an anti-inflammatory and was patented in 1969 and approved for medical use in 1985. The US Food and Drug Administration considers it to be a first-in-class medication for Duchenne Muscular Dystrophy.